Michael Bolick is president of Lab21, a personalized medicine diagnostic specialist supporting healthcare providers, the pharmaceutical and biotechnology industries with technically advanced products and services. Lab21 delivers a rapidly growing portfolio of molecular and viral diagnostics, plus pharmacogenetic and patient profiling tests, which all use cutting-edge technology. This unique combination adds value to early stage drug development, clinical trials and regulatory processes in the pharmaceutical industry and helps clinicians and healthcare providers treat and monitor patients. Bolick was recently inducted into the Liberty Fellowship Class of 2011. Liberty Fellowship is a program designed specifically for emerging state leaders to reinforce values necessary to lead an exemplary life both personally and professionally. Prior to Lab21, Bolick founded Selah Technologies, LLC in 2006 to commercialize nanotechnologies licensed from Clemson University. Selah focused these nanotechnologies to disrupt the molecular imaging market to enable doctors to see cancer during surgery. Selah Technologies was acquired by Lab21 in 2009. Bolick was an executive in the pharmaceutical industry prior to founding Selah. He earned a bachelor of science in chemical engineering at North Carolina State University.